Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic
mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells …

Background Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as
therapeutic targets warranting rapid investigation. Objective This study evaluated the …

Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …

Overwhelming inflammatory reactions contribute to respiratory distress in patients with
COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We …

Clinical immunotherapy approaches are lacking efficacy in the treatment of glioblastoma
(GBM). In this study, we sought to reverse local and systemic GBM-induced …

Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), polycythemia
vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell …

Background The phase 3b, randomised, open-label RESPONSE-2 study in patients with
inadequately controlled polycythaemia vera without splenomegaly showed superiority of the …

Abstract Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …